SII seeks DCGI s permission to manufacture Sputnik V
ANI
03 Jun 2021, 19:18 GMT+10
By Shalini BhardwajNew Delhi [India], June 3 (ANI): Indian vaccine manufacturing company Serum Institute of India (SII) has sought permission from the Drug Controller General of India (DCGI) for the production of the Russian vaccine Sputnik V in India.
SII has applied for a test license to manufacture the COVID-19 vaccine.
Currently, Dr Reddy s Lab is the Russian Direct Investment Fund (RDIF) partner, which markets the Sputnik V vaccine in India.
RDIF and Dr Reddy s Laboratories had in a joint statement said , Dr Reddy s Laboratories is the brand custodian of the Sputnik V vaccine in India and has the sole distribution right of the first 250 million doses ( first and second dose components included) of the vaccine in India, SII is currently involved in the production of Astrazenaca s Covishield and Novavax.
New Delhi [India], June 3 (ANI): Indian vaccine manufacturing company Serum Institute of India (SII) has sought permission from the Drug Controller General of India (DCGI) for the production of the Russian vaccine Sputnik V in India.
While China s another 9 vaccines are only in the first or second phase of human trials, the data says another 17 vaccines from different parts of the world are in the final Phase III stage, which means these vaccines are likely to be available commercially in the coming months. Prominent among them are Zycov-D from India s Zydus Cadila which is expected to be launched in the coming months and Hyderabad-based manufacturer Biological E s BECOV2, which got final phase trial clearance from the Drug Controller General of India (DCGI) last week. Serum Institute, in partnership with US-based Novavax is planning to launch a vaccine by September and its entire production and development was supported by Serum. The vaccine will be manufactured in Pune and at a facility serum sold to Novovax in Europe.